• Myeloma Clinical Trials
    • May 01, 2017

    Clinical Trial: An Early Study with a New Immunomodulator (CC-220) With or Without Dex for Relapsed/Refractory Multiple Myeloma Patients

This is a multicenter, multicountry, open-label, Phase 1b/2a dose-escalation study to determine the maximum tolerated dose of CC-220 when administered as a single therapy and in combination with dexamethasone. CC-220 is a new immunomodulator being developed by Celgene Corporation. The IMiDs are a backbone class of therapies for multiple myeloma. CD-220, also called iberdomide, affects the Cereblon pathway which is one of the mechanisms of action for the immunomodulator drugs. 

There are 3 active sites for this trial: The Mayo Clinic Scottsdale, the Karmanos Cancer Institute and at the Winship Cancer Institute.

Learn more and find the closest trial site here:

To find all eligible clinical trials for your myeloma, click here: 

About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

MYELOMA CROWD RESEARCH INITIATIVE
$52,448 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

Get Started Today.

Find a Clinical Trial that's Right for You

Thanks to our site sponsors: